[HTML] cell.comFull View

[HTML][HTML] Genomic features of response to combination immunotherapy in patients with advanced non-small-cell lung cancer

MD Hellmann, T Nathanson, H Rizvi, BC Creelan…�- Cancer cell, 2018 - cell.com
Combination immune checkpoint blockade has demonstrated promising benefit in lung
cancer, but predictors of response to combination therapy are unknown. Using whole-exome�…
Save Cite Cited by 944 Related articles

Genomic Features of Response to Combination Immunotherapy in Patients with Advanced Non-Small-Cell Lung Cancer.

MD Hellmann, T Nathanson, H Rizvi, BC Creelan…�- Cancer Cell, 2018 - europepmc.org
Combination immune checkpoint blockade has demonstrated promising benefit in lung
cancer, but predictors of response to combination therapy are unknown. Using whole-exome�…
Cite

Genomic features of response to combination immunotherapy in patients with advanced non-small-cell lung cancer

MD Hellmann, T Nathanson, H Rizvi, BC Creelan… - 2018 - crick.figshare.com
Combination immune checkpoint blockade has demonstrated promising benefit in lung
cancer, but predictors of response to combination therapy are unknown. Using whole-exome�…
Cite

Genomic Features of Response to Combination Immunotherapy in Patients with Advanced Non-Small-Cell Lung Cancer

MD Hellmann, T Nathanson, H Rizvi…�- Cancer�…, 2018 - ohiostate.elsevierpure.com
Combination immune checkpoint blockade has demonstrated promising benefit in lung
cancer, but predictors of response to combination therapy are unknown. Using whole-exome�…
Cite
[HTML] nih.gov

[HTML][HTML] Genomic Features of Response to Combination Immunotherapy in Patients with Advanced Non-Small-Cell Lung Cancer

MD Hellmann, T Nathanson, H Rizvi, BC Creelan…�- Cancer Cell, 2018 - ncbi.nlm.nih.gov
Combination immune checkpoint blockade has demonstrated promising benefit in lung
cancer, but predictors of response to combination therapy are unknown. Using whole-exome�…
Cite
[HTML] sciencedirect.com

[HTML][HTML] Genomic Features of Response to Combination Immunotherapy in Patients with Advanced Non-Small-Cell Lung Cancer

MD Hellmann, T Nathanson, H Rizvi, BC Creelan…�- Cancer Cell, 2018 - Elsevier
Combination immune checkpoint blockade has demonstrated promising benefit in lung
cancer, but predictors of response to combination therapy are unknown. Using whole-exome�…
Cite
[PDF] core.ac.uk

[PDF][PDF] Genomic Features of Response to Combination Immunotherapy in Patients with Advanced Non-Small-Cell Lung Cancer

MD Hellmann, T Nathanson, H Rizvi, BC Creelan…�- Cancer Cell, 2018 - core.ac.uk
Combination immune checkpoint blockade has demonstrated promising benefit in lung
cancer, but predictors of response to combination therapy are unknown. Using whole-exome�…
Cite

Genomic Features of Response to Combination Immunotherapy in Patients with Advanced Non-Small-Cell Lung Cancer

MD Hellmann, T Nathanson, H Rizvi, BC Creelan…�- Cancer Cell, 2018 - discovery.ucl.ac.uk
Combination immune checkpoint blockade has demonstrated promising benefit in lung
cancer, but predictors of response to combination therapy are unknown. Using whole-exome�…
Cite
[PDF] scienceopen.com

[PDF][PDF] Genomic Features of Response to Combination Immunotherapy in Patients with Advanced Non-Small-Cell Lung Cancer

MD Hellmann, T Nathanson, H Rizvi, BC Creelan…�- Cancer Cell, 2018 - scienceopen.com
Combination immune checkpoint blockade has demonstrated promising benefit in lung
cancer, but predictors of response to combination therapy are unknown. Using whole-exome�…
Cite

Genomic Features of Response to Combination Immunotherapy in Patients with Advanced Non-Small-Cell Lung Cancer

MD Hellmann, T Nathanson, H Rizvi…�- Cancer�…, 2018 - pubmed.ncbi.nlm.nih.gov
Combination immune checkpoint blockade has demonstrated promising benefit in lung
cancer, but predictors of response to combination therapy are unknown. Using whole-exome�…
Cite